RA Capital Management, L.P. 13D and 13G filings for Vaxcyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 4:51 pm Purchase |
2025-03-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 12,964,491 9.900% |
314,763 (+2.49%) |
Filing |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 12,649,728 9.990% |
2,964,649 (+30.61%) |
Filing |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 9,685,079 9.990% |
1,531,520 (+18.78%) |
Filing |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 8,153,559 9.990% |
4,287,751 (+110.91%) |
Filing |
| 2021-03-30 4:43 pm Purchase |
2021-03-24 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 3,865,808 7.530% |
155,109 (+4.18%) |
Filing |
| 2021-02-16 4:39 pm Sale |
2020-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA Capital Management, L.P. | 3,710,699 7.300% |
-1,778,482 (-32.40%) |
Filing |